Development of siRNA libraries for antiviral discovery
Development of siRNA libraries for antiviral discovery
批准号:
6789086
负责人:
ROGER L KASPAR
金额:
$29.47万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-01 至 2005-03-31
关键词:
RNARNA interferenceantiviral agentsbiotechnologycell linedengue virusdrug discovery /isolationganciclovirgene induction /repressiongene targetinggenetic libraryherpes simplex virus 1high throughput technologymessenger RNAmethod developmentnucleic acid purificationnucleic acid sequencepolymerase chain reactionsmall interfering RNAthymidine kinasetransfection
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The discovery and development of RNA interference and especially the breakthrough of using small interfering RNAs (siRNA) to inhibit gene expression is revolutionizingbiology and opening new avenues for developing novel therapeutics. Despite the current usefulness of the technology, a bottleneck exists for quickly finding effective siRNA target sites in a high throughput-like manner and most researchers currently employ a rational trial-and-error design method. In this proposal, we present a novel cell-based technology to identify effective inhibitors from siRNA libraries (either random or directed). The combination of using a
library to find the most effective, robust siRNAs against accessible sites on any given target within a cellular environment, coupled with the inhibitor activity intrinsic to siRNAs, holds great promises in finding effective therapeutics. We have chosen dengue virus, a NIAID Class A threat, as our initial target for developing this technology. Potential target dengue viral sequences will be linked to the HSV thymidine kinase (TK) gene and stably expressed in human cells. Addition of ganciclovir leads to cell killing of any cell expressing the HSV TK protein. Prior to addition of ganciclovir, a proprietary library of siRNAs designed to only target dengue sequences ("directed" library)will be introduced into the cells. Those cells that subsequently survive
the killing challenge will be isolated and the rescued siRNAs identified. Among the purified and validated inhibitorsidentified, the most potent anti-dengue siRNAs will be further tested for their anti-dengue viral activity in cell-based and animal models. This approach could potentially be extended to any RNA target of interest, including other viruses and oncogene mRNAs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Topical sirolimus Phase 1b trial for pachyonychia congenita (IND number 117347)
-
批准号:8950761
-
项目类别:
-
资助金额:$19.94万
-
财政年份:2015
-
负责人:ROGER L KASPAR
-
依托单位:
Development of topical formulations for delivery of next generation mTOR inhibito
-
批准号:8782436
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:ROGER L KASPAR
-
依托单位:
Evaluation of siRNA uptake and functional activity in a human organotypic skin mo
-
批准号:7915054
-
项目类别:
-
资助金额:$34.09万
-
财政年份:2010
-
负责人:ROGER L KASPAR
-
依托单位:
Pachyonychia congenita clinical trial using therapeutic siRNAs
-
批准号:7539266
-
项目类别:
-
资助金额:$31.27万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs
-
批准号:8203881
-
项目类别:
-
资助金额:$208.8万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs
-
批准号:8336922
-
项目类别:
-
资助金额:$97.34万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
In vivo imaging models for evaluating siRNA delivery to skin
-
批准号:7405503
-
项目类别:
-
资助金额:$14.82万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
Development of topical rapamycin as a novel treatment for skin disorders
-
批准号:7481638
-
项目类别:
-
资助金额:$22.63万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs
-
批准号:8530953
-
项目类别:
-
资助金额:$104.58万
-
财政年份:2008
-
负责人:ROGER L KASPAR
-
依托单位:
Development of RNA-based topical psoriasis inhibitors
-
批准号:6935527
-
项目类别:
-
资助金额:$28.59万
-
财政年份:2005
-
负责人:ROGER L KASPAR
-
依托单位:
Redirection of Fas splicing as a cancer therapy
-
批准号:6934816
-
项目类别:
-
资助金额:$2.27万
-
财政年份:2003
-
负责人:ROGER L KASPAR
-
依托单位:
Redirection of Fas splicing as a cancer therapy
-
批准号:6691155
-
项目类别:
-
资助金额:$29.2万
-
财政年份:2003
-
负责人:ROGER L KASPAR
-
依托单位:
Inhibition of hepatitis C by RNA Lassos
-
批准号:6690614
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2003
-
负责人:ROGER L KASPAR
-
依托单位:
Inhibition of hepatitis C by RNA Lassos
-
批准号:6784661
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2003
-
负责人:ROGER L KASPAR
-
依托单位:
TARGETED MRNA CLEAVAGE BY 3 TRNASE AND SMALL GUIDE RNAS
-
批准号:2605397
-
项目类别:
-
资助金额:$11.1万
-
财政年份:1998
-
负责人:ROGER L KASPAR
-
依托单位:
海外基金